Safe NAD
How safe is more NAD+?
A cell needs help repairing damage. A growing cancer needs resources too. The word “safe” gets interesting when those needs meet.
NAD+ transport in mouse liver
A mouse liver experiment supplies an awkward starting point for a site called Safe NAD. Researchers deleted SLC25A47, a transporter involved in moving NAD+ into mitochondria, the cell's energy-producing structures. The mice developed more liver fat and more tumors. Disrupting that local supply made things worse.
Then comes a different concern: because NAD+ supports growing cells, raising its availability might also help an existing cancer. That is a theoretical, context-dependent concern from laboratory biology, described in the review of NAD+ in health and disease; it is not a finding that precursor pills caused cancer in people.
Neither possible ending satisfies me. A molecule involved in protecting cells can have complicated consequences when the cells are already unhealthy. “More” leaves a great deal unsaid.
The liver experiment involved mice and a deleted transporter. It tested neither a supplement nor a human cancer treatment.
What is NAD+?
Nicotinamide adenine dinucleotide is a coenzyme, a small helper that enzymes need to do their work. NAD+ carries electrons during energy metabolism and also gets consumed by proteins involved in DNA repair and the regulation of cell activity. Those jobs explain the interest in replenishing it.
Cells recycle some NAD+ and manufacture replacements for what they spend. Vitamin B3 ingredients and other starting materials feed that production, as described in the review of NAD+ metabolism. NAD+ itself has a dinucleotide structure; peptides have chains of amino acids.
Repair sounds reassuring. The leap from an essential cellular job to a broadly beneficial intervention leaves me unconvinced. Biology has to do more work before that conclusion is earned.
NAD supplement studies
Most oral research uses a NAD+ precursor: an ingredient the body can turn into NAD+. NMN and NR are the main names in these trials. An 8-week NR trial in healthy overweight adults found higher whole-blood NAD+ with no significant adverse-event difference from placebo. A 60-day NMN trial in healthy middle-aged adults reported higher blood NAD+, improved walking distance and better quality-of-life scores.
These are encouraging observations with specific boundaries. The 2025 review of human precursor trials found limited clinical efficacy and sparse evidence about NAD+ inside particular tissues. That tissue gap matters especially to a safety question that began inside a mouse liver.
I welcome those measured improvements, and the consequences of sustained cellular support deserve equally serious examination. The NMN vs NR comparison puts the human results together.
Preparation adds another safety question
The biology of NAD+ and the quality of an injectable preparation require separate attention. NAD+ has no FDA approval as a drug. Elevated bacterial endotoxin, harmful material from bacteria, prompted a recall of a compounded NAD+ injection in the FDA's most serious category, Class I. Oral precursor trials cannot establish the quality of an injection.
The NAD+ safety page covers that documented preparation risk, reported side effects and the NMN supplement-status dispute. For the repair-and-growth question behind the site's name, continue with cell survival and cancer.